Krishna Institute of Medical Sciences Ltd. (KIMS) is a prominent healthcare institution in India, founded in 2000 by Dr. Bhaskar Rao Bollineni. Over the years, KIMS has expanded its footprint, operating a network of 12 hospitals across Andhra Pradesh, Telangana, and Maharashtra. It offers a comprehensive range of medical and surgical services, with specialties in areas such as renal and cardiac sciences, oncology, orthopedics, neurosciences, and organ transplantation. KIMS’ patient-centric approach and its focus on advanced medical technologies have enabled it to build a strong reputation in India’s healthcare sector.
The flagship hospital in Secunderabad, Telangana, serves as the cornerstone of KIMS’ healthcare services. With a bed capacity of 1,000 beds, including 885 operational beds, this multi-specialty facility is accredited by NABH and certified with ISO 9001:2015 standards. KIMS Secunderabad has earned recognition for its nursing excellence and overall healthcare services, reflecting the organization’s commitment to delivering quality and affordable care. Through its consistent growth and focus on clinical excellence, KIMS continues to enhance its presence, catering to the diverse medical needs of patients across the region.
Latest News on Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences (KIMS) has recently inked a ₹700-crore medical technology procurement deal with Wipro GE Healthcare, marking a significant milestone in enhancing its medical infrastructure. The Memorandum of Understanding, signed on October 18, 2024, spans three years and covers both the acquisition of new advanced medical equipment and the servicing of existing ones for KIMS’ 12 hospitals and four upcoming facilities. This strategic partnership includes cutting-edge technologies such as PET CTs, SPEC CTs, Cath labs, MRIs, CT scanners, ultrasounds, and critical care equipment. Wipro GE Healthcare will provide end-to-end support, leveraging its local manufacturing and service network. Dr. Bhaskar Rao, KIMS’ Chairman and Managing Director, emphasized the partnership’s importance in expanding healthcare services across Southern and Western India. Meanwhile, Chaitanya Sarawate, Managing Director of Wipro GE Healthcare, highlighted how the collaboration aligns with both organizations’ mission to improve healthcare accessibility. Despite the major announcement, KIMS’ stock price remained relatively unchanged, trading at ₹542.30 on the NSE following the news.
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
Promoters + | 38.85% | 38.82% | 38.82% | 38.82% | 38.82% |
FIIs + | 14.24% | 15.27% | 16.73% | 17.84% | 15.85% |
DIIs + | 34.80% | 34.24% | 33.13% | 32.12% | 32.29% |
Public + | 12.10% | 11.67% | 11.32% | 11.22% | 13.03% |
No. of Shareholders | 66,957 | 71,014 | 69,092 | 69,063 | 77,617 |
The shareholding pattern of Krishna Institute of Medical Sciences (KIMS) over the period from December 2021 to September 2024 shows a stable and diversified ownership structure. The promoters have maintained a consistent stake of around 38.84%-38.85% during this time, demonstrating their strong long-term commitment to the company.
Foreign Institutional Investors (FIIs) have shown some fluctuations, beginning with 8.44% in December 2021, peaking at 20.50% in December 2022, and settling at 15.85% by September 2024. This volatility reflects FIIs’ dynamic investment strategies, likely influenced by market conditions and the company’s financial performance.
Domestic Institutional Investors (DIIs) have steadily increased their shareholding, rising from 20.87% in December 2021 to 35.77% in June 2023. This trend suggests strong confidence from local institutions in KIMS’ long-term growth potential, though their holdings slightly decreased to 32.29% by September 2024.
The public shareholding has decreased over time, dropping from 31.84% in December 2021 to 13.03% in September 2024. This indicates a shift towards institutional control, as both FIIs and DIIs have increased their stakes. Additionally, the number of shareholders has also varied, rising from 74,355 in December 2021 to 77,617 in September 2024, showing a growing interest in the company.
Overall, the evolving shareholding pattern reflects increasing institutional interest and confidence in Krishna Institute of Medical Sciences‘ growth trajectory, with the company’s promoter stake remaining stable throughout the period.
Below are the trading platforms that you can use to purchase Krishna Institute of Medical Sciences shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
When | Maximum Price | Minimum Price |
October 2024 | 563.35 | 489.87 |
November 2024 | 585.89 | 509.47 |
December 2024 | 591.75 | 514.56 |
In October 2024, Krishna Institute of Medical Sciences is projected to experience a maximum price of ₹563.35 and a minimum price of ₹489.87. Moving forward to November 2024, the expected price range widens, with a maximum of ₹585.89 and a minimum of ₹509.47. Finally, as we step into December 2024, Krishna Institute of Medical Sciences is expected to see its share prices peak at ₹591.75, with a minimum price of ₹514.56. These projections highlight a gradual increase in both maximum and minimum prices towards the end of the year.
When | Maximum Price | Minimum Price |
January 2025 | 597.66 | 459.74 |
February 2025 | 603.70 | 464.39 |
March 2025 | 616.38 | 474.14 |
April 2025 | 610.28 | 469.44 |
May 2025 | 592.50 | 455.77 |
June 2025 | 619.16 | 476.28 |
July 2025 | 607.02 | 466.94 |
August 2025 | 625.80 | 481.38 |
September 2025 | 633.31 | 487.16 |
October 2025 | 649.77 | 499.83 |
November 2025 | 666.02 | 512.32 |
December 2025 | 695.99 | 535.38 |
As we move into 2025, Krishna Institute of Medical Sciences is expected to experience a maximum price of ₹597.66 and a minimum of ₹459.74 in January. This trend of increasing values is anticipated to continue, with the maximum price rising to ₹619.16 and a minimum of ₹476.28 by June. By October, the maximum price could reach ₹649.77, with a minimum of ₹499.83. As we approach December 2025, the stock is projected to have a maximum of ₹695.99 and a minimum of ₹535.38.
When | Maximum Price | Minimum Price |
January 2026 | 716.87 | 551.44 |
February 2026 | 698.95 | 537.65 |
March 2026 | 712.92 | 548.40 |
April 2026 | 727.47 | 559.60 |
May 2026 | 720.27 | 554.06 |
June 2026 | 738.28 | 567.91 |
July 2026 | 723.80 | 556.77 |
August 2026 | 746.19 | 573.99 |
September 2026 | 761.11 | 585.47 |
October 2026 | 780.90 | 600.69 |
November 2026 | 800.42 | 615.71 |
December 2026 | 820.43 | 631.10 |
When | Maximum Price | Minimum Price |
January 2027 | 828.64 | 637.41 |
February 2027 | 849.89 | 653.76 |
March 2027 | 883.03 | 679.25 |
April 2027 | 865.72 | 665.94 |
May 2027 | 840.50 | 646.54 |
June 2027 | 878.32 | 675.63 |
July 2027 | 861.10 | 662.39 |
August 2027 | 887.73 | 682.87 |
September 2027 | 918.80 | 706.77 |
October 2027 | 942.69 | 725.15 |
November 2027 | 966.26 | 743.28 |
December 2027 | 990.42 | 761.86 |
When | Maximum Price | Minimum Price |
January 2028 | 1,010.23 | 777.10 |
February 2028 | 1,036.13 | 797.02 |
March 2028 | 1,076.54 | 828.11 |
April 2028 | 1,055.43 | 811.87 |
May 2028 | 1,024.69 | 788.22 |
June 2028 | 1,070.80 | 823.69 |
July 2028 | 1,049.80 | 807.54 |
August 2028 | 1,082.27 | 832.52 |
September 2028 | 1,120.15 | 861.66 |
October 2028 | 1,149.28 | 884.06 |
November 2028 | 1,178.01 | 906.16 |
December 2028 | 1,207.46 | 928.81 |
When | Maximum Price | Minimum Price |
January 2029 | 1,231.61 | 947.39 |
February 2029 | 1,263.19 | 971.68 |
March 2029 | 1,312.45 | 1,009.58 |
April 2029 | 1,286.72 | 989.78 |
May 2029 | 1,249.24 | 960.95 |
June 2029 | 1,305.45 | 1,004.20 |
July 2029 | 1,279.86 | 984.51 |
August 2029 | 1,319.44 | 1,014.95 |
September 2029 | 1,365.62 | 1,050.48 |
October 2029 | 1,401.13 | 1,077.79 |
November 2029 | 1,436.16 | 1,104.74 |
December 2029 | 1,472.06 | 1,132.35 |
When | Maximum Price | Minimum Price |
January 2030 | 1,501.50 | 1,155.00 |
February 2030 | 1,540.00 | 1,184.62 |
March 2030 | 1,600.06 | 1,230.82 |
April 2030 | 1,568.69 | 1,206.68 |
May 2030 | 1,523.00 | 1,171.54 |
June 2030 | 1,591.53 | 1,224.26 |
July 2030 | 1,560.33 | 1,200.25 |
August 2030 | 1,608.58 | 1,237.37 |
September 2030 | 1,664.88 | 1,280.68 |
October 2030 | 1,708.17 | 1,313.98 |
November 2030 | 1,750.87 | 1,346.83 |
December 2030 | 1,794.65 | 1,380.50 |
As we step into 2030, Krishna Institute of Medical Sciences is anticipated to have a maximum price of ₹1,501.50 and a minimum price of ₹1,155.00 in January. The stock is expected to show an upward trend, with the maximum price reaching ₹1,664.88 and a minimum of ₹1,280.68 by September. As we approach December 2030, the maximum price could climb to ₹1,794.65, while the minimum may settle at ₹1,380.50, indicating strong performance throughout the year.
Krishna Institute of Medical Sciences Financial Condition
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
Sales + | 1,123 | 1,330 | 1,651 | 2,198 | 2,498 | 2,581 |
Expenses + | 872 | 953 | 1,126 | 1,587 | 1,850 | 1,918 |
Operating Profit | 251 | 377 | 524 | 611 | 648 | 663 |
OPM % | 22% | 28% | 32% | 28% | 26% | 26% |
Other Income + | 5 | 9 | 27 | 41 | 13 | 15 |
Interest | 44 | 37 | 22 | 37 | 55 | 56 |
Depreciation | 71 | 70 | 73 | 129 | 147 | 153 |
Profit before tax | 141 | 279 | 457 | 485 | 460 | 468 |
Tax % | 18% | 26% | 25% | 25% | 27% | |
Net Profit + | 115 | 205 | 344 | 366 | 336 | 345 |
EPS in Rs | 3.2 | 5.19 | 8.32 | 8.41 | 7.75 | 7.9 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
The financial performance of Krishna Institute of Medical Sciences (KIMS) from March 2020 to the trailing twelve months (TTM) of 2024 shows significant growth, particularly in revenue and operating profit. Sales have consistently increased, growing from ₹1,123 crore in March 2020 to ₹2,581 crore in the TTM period of 2024, reflecting the company’s expanding footprint and service offerings. The rise in expenses has also been notable, from ₹872 crore in March 2020 to ₹1,918 crore in the TTM, which indicates increased operational activities and cost management.
The Operating Profit Margin (OPM) has varied, reaching a peak of 32% in March 2022 before stabilizing at 26% in the TTM period of 2024. Despite this slight decline, KIMS maintained profitability with operating profit improving from ₹251 crore in March 2020 to ₹663 crore in the TTM. Other income has shown fluctuations, peaking at ₹41 crore in March 2023, driven by investments or non-operational income.
The company’s net profit increased significantly, from ₹115 crore in March 2020 to ₹345 crore in the TTM of 2024, although there was a slight dip from its peak in March 2023. Earnings per share (EPS) have reflected this growth, rising from ₹3.2 in March 2020 to ₹7.9 in the TTM. The tax rate has hovered around 25-27%, and Krishna Institute of Medical Sciences has maintained a conservative approach with a 0% dividend payout throughout this period, likely reinvesting profits to fuel further expansion.
FAQS
As of October 19th, 2024, the share price of Krishna Institute of Medical Sciences is around INR ₹540.
Based on various market analyses and expert opinions, the expected share price target of Krishna Institute of Medical Sciences by 2025 is around INR 695.99.
As per our analysis, Krishna Institute of Medical Sciences share price target for 2030 would be somewhere between ₹1,155.00 and ₹1,794.65.
ALSO READ:
- Rajesh Exports Ltd Share Price Target 2024, 2025 to 2030
- Mahindra Lifespace Developers Ltd Share Price Target 2024, 2025 to 2030
- Hindustan Aeronautics Ltd (HAL) Share Price Target 2024, 2025 to 2030
Conclusion
In conclusion, Krishna Institute of Medical Sciences Ltd. (KIMS) has established itself as a leading healthcare institution in India, with a strong commitment to delivering quality medical services across its network of hospitals. The recent partnership with Wipro GE Healthcare, involving a significant ₹700-crore investment in medical technology, further enhances KIMS’ infrastructure and capacity to provide advanced healthcare services.
The shareholding pattern reflects a stable ownership structure, with a consistent promoter stake and growing confidence from institutional investors. Projections indicate a steady increase in share prices over the next several years, highlighting KIMS’ strong growth potential. The financial performance showcases a positive trajectory, with increasing sales and operating profit, though expenses are also rising. Overall, KIMS is well-positioned for continued growth and success in the evolving healthcare landscape in India.
What did we learn?
- 1 Latest News on Krishna Institute of Medical Sciences Ltd
- 2 Shareholdings Patters of Krishna Institute of Medical Sciences (KIMS)
- 3 How to Purchase Krishna Institute of Medical Sciences Ltd Shares?
- 4 Krishna Institute of Medical Sciences Share Price Prediction 2024, 2025 to 2030
- 4.1 Krishna Institute of Medical Sciences Share Price Prediction 2024
- 4.2 Krishna Institute of Medical Sciences Share Price Target 2025
- 4.3 Krishna Institute of Medical Sciences Share Price Prediction 2026
- 4.4 Krishna Institute of Medical Sciences Share Price Target 2027
- 4.5 Krishna Institute of Medical Sciences Share Price Prediction 2028
- 4.6 Krishna Institute of Medical Sciences Share Price Prediction 2029
- 4.7 Krishna Institute of Medical Sciences Share Price Target 2030
- 5 Krishna Institute of Medical Sciences Financial Condition
- 6 FAQS
- 7 Conclusion